Australia markets closed

Apogee Therapeutics, Inc. (APGE)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
50.62+1.11 (+2.24%)
At close: 04:00PM EDT
51.24 +0.62 (+1.22%)
After hours: 04:59PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 2.87B
Enterprise value 2.20B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)3.71
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3143.48%
S&P500 52-week change 323.29%
52-week high 372.29
52-week low 314.19
50-day moving average 346.21
200-day moving average 343.19

Share statistics

Avg vol (3-month) 3450.07k
Avg vol (10-day) 3421.5k
Shares outstanding 543.19M
Implied shares outstanding 659.01M
Float 829.01M
% held by insiders 111.31%
% held by institutions 1122.88%
Shares short (15 Aug 2024) 48.19M
Short ratio (15 Aug 2024) 421.5
Short % of float (15 Aug 2024) 421.29%
Short % of shares outstanding (15 Aug 2024) 414.44%
Shares short (prior month 15 July 2024) 48.61M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)30 June 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-19.30%
Return on equity (ttm)-26.73%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA N/A
Net income avi to common (ttm)-118.48M
Diluted EPS (ttm)-2.09
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)676.23M
Total cash per share (mrq)11.56
Total debt (mrq)4.08M
Total debt/equity (mrq)0.53%
Current ratio (mrq)27.70
Book value per share (mrq)13.23

Cash flow statement

Operating cash flow (ttm)-110.57M
Levered free cash flow (ttm)-71.46M